Datapoint: Padcev Snags Expanded Approvals in Bladder Cancer

The FDA last week granted Seagen Inc. and Astellas Pharma’s Padcev two expanded bladder cancer indications, following a priority review. The antibody-drug conjugate now has regular approval as a third-line treatment for metastatic or locally advanced urothelial cancer, plus a new nod as a second-line therapy for bladder cancer patients who are ineligible for certain types of chemotherapy. For the treatment of bladder cancer, Padcev currently holds covered or better status for 54% of all insured lives under the pharmacy benefit. Under the medical benefit, Padcev is covered or better for 82% of lives.

SOURCE: MMIT Analytics, as of 7/14/

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 31

Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today